Articles tagged with Skin Tumors
Researchers discuss future directions in neuroblastoma treatment, including new approaches for high-risk patients and the development of an international classification system. Current regimens and prognosis are also analyzed, highlighting the need for improved understanding of genomic alterations to guide therapy.
Researchers at Mayo Clinic have found that cryoablation is an effective treatment option for patients who are not good candidates for surgery due to size or location of the tumor. The procedure involves freezing the tumor with argon gas, resulting in short-term success in over 90% of selected patients.
A new study found that triple negative breast cancers are more common among young, poor minority women, particularly African American and Hispanic women. The tumors are also associated with later diagnosis and shorter survival rates, with African American women having the poorest five-year survival rate.
A study by St. Jude Children's Research Hospital found that adults who survived childhood acute lymphoblastic leukemia (ALL) are at a higher risk of developing secondary neoplasms during adulthood. Most of these late-onset tumors are low-grade and curable, but some can cause significant health issues.
Scientists have discovered that a cell-signaling molecule Akt plays a key role in the progression of melanomas from non-invasive to invasive cancers. Understanding this molecular difference could lead to new targets for treating advanced stage melanoma, with a survival rate of 98% for radial melanomas on the surface of the skin.
A study published at the University of Pittsburgh Medical Center found that endoscopic brain surgery is effective in removing life-threatening tumors in children, with minimal complications and no neurological damage. The minimally invasive approach allows for faster recovery times and a shorter hospital stay.
Researchers found that hematopoietic stem cell transplantation enhanced the expansion of tumor-reactive CD8+ T cells, leading to increased tumor regression. The study suggests that this approach may improve treatment regimens for cancer patients.
Researchers identified p38-regulated/activated protein kinase (PRAK) as an essential component mediating ras-induced senescence and tumor suppression. The study found that PRAK activation inhibits tumor development, laying the groundwork for new cancer therapy.
Research suggests that brown algae polyphenols (BAPs) extracted from a marine seaweed can reduce the number of skin tumors by up to 60% and their size by up to 43%. The substances also reduced inflammation, with lower levels of COX-2 and prostaglandin E2 detected in BAP-treated animals.
A study found specific genetic alterations in the stroma of head and neck skin cancers are linked to smoking and tumor aggressiveness. The research identified key genomic regions that may harbor genes related to clinical outcome and targeted therapy.
A study investigated melanoma growth rate in 404 patients and found that fast-growing melanomas are more likely to occur in elderly men and individuals with fewer moles and freckles. The study provides descriptive data on the spectrum of melanoma rates of growth, offering insights into subgroups associated with rapid growth.
Research shows pro-vitamin E, alpha-tocopheryl succinate, reduces tumour volume in experimental animals with high HER2 levels. The compound induces controlled cell death and has the potential to be an effective treatment for hard-to-treat breast cancers.
Researchers at Thomas Jefferson University have found that the protein fragment endorepellin blocks both skin and lung cancer tumors from progressing in animal models by preventing their ability to recruit new blood vessels. Endorepellin has surprisingly powerful effects on halting a cancer tumor's ability to move about and spread.
A study published in the Journal of Biological Chemistry found that signal protein Srcasm can block tumor-promoting molecules in skin cells, potentially leading to targeted gene therapy for certain cancers. By increasing Srcasm levels, researchers may be able to reverse uncontrolled cell growth caused by activated Src kinases.
Researchers at UVA Health System have discovered cancer-testis antigens, called SPANX proteins, which could selectively kill melanoma tumors while sparing the rest of the body's tissues. These antigens may also help develop a vaccine to stimulate the immune system to attack and suppress melanoma tumors.
Researchers found that restoring Ras-GAP activity through expression of the human NF1 GAP-related domain restored normal cardiac development in mice with Neurofibromatosis type I disease. However, this approach did not fully restore all pathologies associated with neurofibromin loss, indicating a more complex role for the protein.
Researchers discovered a cancer triad involving Ras, c-myc, and p21 genes. Mice lacking the c-myc gene showed resistance to skin cancer, while mice with both missing genes regained sensitivity to mutated Ras. This study provides new insights into epithelial tumor development.
Researchers develop computer approach to precisely target breast tumors with electron and x-ray beams, reducing collateral skin damage. The technique helps send accurately targeted doses for 78 patients, providing benefits for shallow tumor treatments in the breast, chest wall, and head-and-neck region.
The study identified two novel proteins, Gpb1 and Gbp2, that regulate the Ras oncogene in humans and yeast. These findings have important medical implications for developing new therapies to prevent neurofibromatosis 1-related cancers.
Researchers found that IVF embryo culture can alter the expression of imprinted genes, potentially leading to abnormalities such as Beckwith Wiedeman syndrome. The study suggests that modifying culture media and oxygen concentrations may improve gene expression.
Combination therapy with a monoclonal antibody (CLTA4 blockade) and a vaccine (Gvax) leads to increased infiltration of CD8+ T effector cells into tumors, resulting in tumor rejection. Chronic exposure to this therapy does not deplete regulatory T cells, preserving their immune-modulating function.
A team of researchers from Munich discovered a cellular mechanism that protects against tumours by controlling the Bcl-3 oncogene. The study identified Cyld as a potential tumour suppressor, which can accumulate around the nucleus and prevent Bcl-3 from entering it.
A team of researchers discovered that CYLD has a second role in controlling tumor growth by modifying the cancer-promoting protein Bcl-3. Mice lacking CYLD developed significantly more and larger skin tumors than normal mice, suggesting that CYLD plays a crucial role as a tumor suppressor.
Research found that exercising mice took longer to develop skin tumors and had fewer tumors than sedentary mice exposed to ultraviolet B light. Exercise was also linked to lower body fat, which decreased the risk of skin cancer.
Studies found that exercise reduced tumour development and improved survival in mice exposed to ultraviolet B light. Exercise also decreased body fat and enhanced programmed cell death in cancer cells. The studies suggest that voluntary exercise may protect against skin and bowel cancers, but more research is needed to confirm this.
Researchers found that freezing kidney tumors using percutaneous cryoablation destroyed 95% of tumors in short-term follow-up. The treatment is performed through small skin nicks and can be done under general anesthesia, offering a less invasive alternative to traditional surgery.
A new study suggests that renal biopsy can help patients avoid kidney removal by identifying benign tumors that don't require surgery. The procedure is safe and effective, with only minor complications reported in the 407 biopsies performed.
Researchers found that 20% of participants developed additional melanoma within one year and 27% within two years after initial diagnosis. Those with atypical moles had a higher risk of developing additional melanomas, with those having three or more atypical moles being four times more likely to develop multiple tumors.
Researchers have found a safer and more effective way to detect and kill cancer cells using gold nanorods. The new method allows for deeper penetrating noninvasive cancer treatment without harming healthy cells, making it a promising approach for treating breast cancer.
Researchers have identified new molecular indicators of aging in the skin that could be used to evaluate anti-aging therapies. The biomarkers are changes to the DNA of cellular organelles called mitochondria and correlate with the aging process.
L2G7 successfully causes brain tumor regression and improves animal survival in pre-clinical models. The monoclonal antibody targets key tumor growth factor hepatocyte growth factor (HGF), promoting cancer malignancy.
Scientists identify Langerhans cell precursor cells and protein Csf-1 essential for their transformation. This discovery may lead to new therapies for patients with Langerhans histocytosis, a rare disease affecting approximately 200,000 children annually.
The incidence of invasive melanoma has significantly increased among Hispanic males in California between 1988 and 2001. The rate of invasive tumors greater than 0.75mm thick is particularly concerning, with a notable increase among Hispanic men compared to non-Hispanic whites.
Researchers found two sequences in Gli1 protein that prevent its degradation, leading to accelerated tumorigenesis and shorter tumor latency. This discovery may represent a novel anticancer therapy by modulating Gli protein stability.
A new spinal surgery technique, developed by UCSF neurosurgeon Christopher Ames, allows for direct access to cervical spinal tumors without neural manipulation. The procedure involves removing and reconstructing portions of the cervical spine to access tumors, providing a minimally invasive option for patients with conditions like neur...
Researchers at Columbia University Irving Medical Center have developed a new type of virus, called a
Melanoma cells can efficiently spread due to reactivation of dormant Slug gene, which enables swift travel through the body. This discovery sheds light on why melanoma metastasizes at an earlier stage than other cancers.
Researchers found that matriptase, a cell surface enzyme, triggers the formation of tumor cells and promotes rapid cell division. The study suggests that targeting matriptase could be an effective way to treat various types of cancer.
A Mayo Clinic study found that basal cell carcinoma (BCC) tumors are increasing in younger adults, with a significant surge in women over 30. Squamous cell carcinoma (SCC) diagnoses also rose sharply, especially among men and women in their late 30s. Long-term sun exposure and tanning bed use are major contributors to this trend.
Research has found a positive association between body mass index, fat-free mass, and waist circumference with an increased risk of myeloid leukemia. Additionally, modifications of the vimentin gene can be detected in fecal DNA of people with colon cancer, potentially serving as a biomarker for the disease.
The number of new melanoma cases in the US increased 60% from 1988-1991 to 1996-1999, with thick melanomas primarily composed of nodular subtype. The study suggests that current early-detection educational programs may not be effective for detecting this aggressive type of melanoma.
A phase I study found that glioma patients who responded to erlotinib treatment had higher levels of EGFR expression and amplification. The level of phosphorylated PKB/Akt was also associated with response to erlotinib, as well as time to progression.
A study found that inhibiting EGFR with gefitinib can reduce breast tumor size by 30-99% in some cases. Researchers are now designing studies to assess the potential of this approach as a neoadjuvant treatment for breast cancer.
Researchers test a new therapy for advanced melanoma, delivering a DNA plasmid through electroporation to stimulate the immune system. The results show high success in curing mice and preventing tumor regrowth.
The researchers created nano-sized probes using emissive polymersomes that can optically image tissue structures deep below the skin, with potential to target multiple cancer cell-surface markers simultaneously. The probes use near-infrared light to produce a bright signal detectable through imaging systems.
Researchers found that vaccination against tumor-specific proteins can reinvigorate existing T cells, allowing them to attack tumors. This breakthrough suggests a new approach to treating skin cancer by targeting the immune system's natural defense mechanisms.
Researchers have identified a subset of tumor cells that resist inhibition of the Hedgehog signaling pathway, leading to cancer recurrence. However, targeting these residual cell populations could lead to effective treatment of basal cell carcinoma.
Researchers at MIT have created a new mouse model of cancer syndrome by introducing point mutations in the tumor suppressor gene p53. The study shows that these subtle mutations can lead to a broad range of tumors in mice, potentially providing insights into treating cancers with similar genetic profiles.
Researchers at Johns Hopkins Medicine found that stressed mice develop skin cancer faster than non-stressed mice. Stress-reducing programs like yoga and meditation may help individuals at high risk for skin cancer stay healthy longer.
Researchers found that activated STAT3 is necessary for skin cancer development, and inhibiting it can prevent tumor growth. A STAT3 inhibitor could potentially be used as a topical cream to treat sunburns or precancerous lesions.
Researchers found that mice with brain tumors treated with stem cells showed increased blood supply and decreased tumor growth, living on average 50 percent longer than untreated mice. The Congress of Neurological Surgeons Annual Meeting presented this promising research.
Intensity modulated radiation therapy (IMRT) significantly reduces radiation dose to healthy breast tissue, limiting side effects and improving treatment outcomes. By administering precise doses of radiation at the tumor site, IMRT can spare patients from skin irritation, breakdown, and scarring of the lungs.
A new targeted cancer treatment, cetuximab, has shown improved response rates and survival times in advanced colorectal cancer patients who develop an acne-like rash. The study found that the severity of the rash correlated with better tumour responses and longer median survival times.
A Phase II study has shown that the drug imatinib is active against a rare type of cancer called DFSP, achieving complete control in eight out of ten patients. The research team believes molecular analysis can predict patient response to treatment based on genetic profiles.
Vascular tumor growth in children is linked to a protein called MCP-1 that recruits macrophages, stimulating angiogenesis and tumor growth. Anti-MCP-1 therapy may prevent tumor development and improve patient outcomes.
A new study found that Akt pathway activation is associated with better response rates and reduced disease progression in lung cancer patients treated with gefitinib. The researchers identified P-Akt positivity as a key marker for predicting patient response, but not P-MAPK positivity.
Scientists at Mayo Clinic develop novel approach to cancer vaccine that leverages inflammatory cell death to trigger a strong anti-tumor immune response, eradicating skin cancer tumors without triggering autoimmune disease. The breakthrough sheds light on a major obstacle in advancing cancer vaccine research from lab to human trials.
Scientists successfully designed and tested nanoparticles to both target and visualize prostate tumors in mice, offering potential for early cancer detection and treatment. The breakthrough uses a unique coating to protect the particles from degradation and enhance their targeting capabilities.
Researchers used nanoshells to destroy tumors with heat from near-infrared light, showing promising results in a first animal test. All tumors disappeared within 10 days in the treated group, while untreated and saline-treated groups continued to grow.
Lapatinib, a new breast cancer drug, has shown promising results in shrinking tumors or slowing growth in 46% of patients. The medication targets both Her-2 and Epidermal Growth Factor (EGFR) receptors, which blocks cell signaling and inhibits tumor growth